Panakeia to attend and present at upcoming scientific and business conferences
- Stella Lempidaki
- Apr 9
- 2 min read
Cambridge, UK, 9 April 2025 – Panakeia (“the Company”), a pioneer in AI-enabled multi-omic biomarker profiling, is pleased to confirm that it will be attending and presenting at a number of conferences as detailed below.
CB & CDx Summit Europe, April 8-10, London, UK
Corporate presentation, April 9 at 4.30pm GMT
Title: H&E-based molecular profiling: from bench to bedside in the era of precision medicine and AI
AACR Annual Meeting - April 25-30, Chicago, IL, US
ESMO Breast Cancer - May 14-17, Munich, Germany
Annual Transforming Digital Pathology & AI: The Path Forward - May 15, Edinburg, UK
ASCO Annual Meeting - May 30 - June 5, Chicago, IL, US
If you would like to meet with the Panakeia team in any of the above conferences, please get in touch via the contact form on our website.
About Panakeia
Panakeia is a pioneer in AI-enabled molecular profiling. The Company’s AI-driven software provides comprehensive multi-omic information (DNA, RNA, protein, metabolite changes) directly from routinely used images of tissues and cells in minutes instead of days or weeks. The software enables same-day treatment decision-making in the clinic and fast-tracks drug development for biopharma without the need for time and resource intensive laboratory tests.
Panakeia’s PANProfiler platform is available as a research use tool for patient screening in clinical trials. The Company’s two clinical products for breast and colon cancers are built using the PANProfiler platform. These products are approved and clinically deployed in the UK with several more products in the pipeline.
Headquartered in Cambridge, UK, Panakeia is focused on improving the speed and accuracy of pathology examinations for all patients.
To learn more about Panakeia’s platform visit: https://www.panakeia.ai/
For more information please contact:
Stella Lempidaki, PhD
Head of Communications
Comments